Notably, transforming growth factor-beta (TGF-β), abundantly present in the tumor microenvironment, downregulates the expression of key NK cell–activating receptors such as NKG2D and NKp30, thereby compromising tumor cell recognition and cytolytic function (32–36). Here, NCR3 is linked to neoplasm.